Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine

被引：6

作者：

Erdogdu, Batuhan ^{[1
]}

Cinar, Olgu Erkin ^{[1
]}

Malkan, Umit Yavuz ^{[1
]}

Aksu, Salih ^{[1
]}

Demiroglu, Haluk ^{[1
]}

Buyukasik, Yahya ^{[1
]}

Goker, Hakan ^{[1
]}

Sayinalp, Nilgun ^{[1
]}

Haznedaroglu, Ibrahim Celalettin ^{[1
]}

机构：

[1] Hacettepe Univ, Fac Med, Dept Hematol, Ankara, Turkey

来源：

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | 2022年 / 32卷 / 01期

关键词：

D O I：

10.4999/uhod.226097

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Our second case is a 49-year-old female patient, two days after receiving BNT162b2 mRNA COVID-19 vaccine, petechiae was started in arms and then in lower extremities. The complaints of weakness and fatigue continued to increase within days. The patient, who was admitted to the hospital ten days later with these complaints, was found to have bi-cytopenia. Bone marrow aspiration and biopsy reported that 20-30% stained with cd19 diffuse positive Terminal deoxynucleotidyl transferase (TdT) in blastic cells. HyperCVAD chemotherapy was started with the diagnosis of b-acute lymphoOur third case is a 57-year-old male patient, difficulty in swallowing, and oral ulceration after vaccination of BNT162b2 mRNA COVID-19 vac

引用

页码：65 / 67

页数：3

共 50 条

[21] Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
Ramirez-Garcia, Almudena
Jimenez, Sara Lozano
Ximenez, Ignacio Darnaude
Cacho, Alberto Gil
Aguado-Noya, Ramon
Cubero, Javier Segovia
REVISTA ESPANOLA DE CARDIOLOGIA, 2021, 74 (12): : 1121 - +
[22] Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine REPLY
Waxman, Jacob G.
Magen, Ori
Hernan, Miguel A.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02): : 192 - 192
[23] Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
Choe, Young June
Yi, Seonju
Hwang, Insob
Kim, Jia
Park, Young-Joon
Cho, Eunhee
Jo, Myoungyoun
Lee, Hyunju
Choi, Eun Hwa
VACCINE, 2022, 40 (05) : 691 - 694
[24] Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
Juddoo, Vanessa
Juddoo, Sonia
Megarbane, Bruno
VACCINE, 2022, 40 (19) : 2650 - 2651
[25] Effects of BNT162b2 mRNA Covid-19 vaccine on vascular function
Yamaji, Takayuki
Harada, Takahiro
Hashimoto, Yu
Nakano, Yukiko
Kajikawa, Masato
Yoshimura, Kenichi
Goto, Chikara
Han, Yiming
Mizobuchi, Aya
Yusoff, Farina Mohamad
Kishimoto, Shinji
Maruhashi, Tatsuya
Nakashima, Ayumu
Higashi, Yukihito
PLOS ONE, 2024, 19 (04):
[26] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine REPLY
Absalon, Judith
Koury, Kenneth
Gruber, William C.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1578 - 1578
[27] Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Walton, Muireann
Pletzer, Vadim
Teunissen, Thomas
Lumley, Thomas
Hanlon, Timothy
DRUG SAFETY, 2023, 46 (09) : 867 - 879
[28] Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Muireann Walton
Vadim Pletzer
Thomas Teunissen
Thomas Lumley
Timothy Hanlon
Drug Safety, 2023, 46 : 867 - 879
[29] Leukocytoclastic vasculitis in possible relation to the BNT162b2 mRNA COVID-19 vaccine
Carrillo-Garcia, Pamela
Sanchez-Osorio, Luisa
Gomez-Pavon, Javier
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (04) : 971 - 973
[30] Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
Mevorach, D.
Anis, E.
Cedar, N.
Bromberg, M.
Haas, E. J.
Nadir, E.
Olsha-Castell, S.
Arad, D.
Hasin, T.
Levi, N.
Asleh, R.
Amir, O.
Meir, K.
Cohen, D.
Dichtiar, R.
Novick, D.
Hershkovitz, Y.
Dagan, R.
Leitersdorf, I
Ben-Ami, R.
Miskin, I
Saliba, W.
Muhsen, K.
Levi, Y.
Green, M. S.
Keinan-Boker, L.
Alroy-Preis, S.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (23): : 2140 - 2149

← 1 2 3 4 5 →